Sign in

or Register now

MyRACentral.com

See all of our health sites at www.HealthCentral.com
Friday, October 10, 2008

Drug combo taken early relieves migraine

Wednesday, Jul. 9, 2008; 3:26 AM

NEW YORK (Reuters Health) - A combination drug taken within an hour after the start of a migraine headache provides effective relief of pain and other symptoms for up to 24 hours, researchers report in the journal Neurology this week.

The drug combines sumatriptan, a migraine-specific drug that affects the constriction of blood vessels, with naproxen, a non-steroidal anti-inflammatory drug that works on the inflammatory aspect of migraine and relieves non-traditional migraine symptoms such as sinus pain and pressure and neck pain.

"Unfortunately, many migraine sufferers put off treatment," Dr. Stephen Silberstein of the Thomas Jefferson University in Philadelphia said in a written statement. "This study provides more evidence that treating a migraine at the first sign of pain increases the likelihood of relief."

Silberstein and colleagues conducted two studies with a total of 1,111 people with migraine who had suffered two to six attacks per month in the three months before the study started.

Half of the study subjects were given the sumatriptan/naproxen drug within an hour after migraine pain started and while the pain was still mild; the other half were given a placebo.

Two hours after the dose was given, about 50 percent of those who received the drug combo were free of any pain, compared to about 16 percent of those who got the placebo. The people who took the placebo were also two to three times more likely to progress to moderate or severe pain over four hours than those who took the drug combo.

Subjects who took the drug combo also had fewer traditional migraine-related symptoms such as nausea and sensitivity to light and sound and fewer non-traditional symptoms such as neck and sinus pain than those who took the placebo.

SOURCE: Neurology, July 8, 2008.


Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Ask a Question

Get answers from our experts and community members.

Answer a Question

Is anyone with RA on SSD?

Answer This View all questions >
Free Newsletter
Get weekly updates, news alerts and more on Rheumatoid Arthritis and related health conditions.